

PATENT APPICATION DOCKET NO.: 00537-191002

.: 00537-191002 093/US/PCT2AUS CH CENTER 1600/29

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Dean Sadat-Aalaee et al.

Application No.: 09/980,943

Group Art Unit: 1615

Filed:

February 22, 2002

Examiner:

Unknown

Title:

SOMATOSTATIN AGONISTS

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit:

1st SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO **CHARGE DEPOSIT ACCOUNT**

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:				
This In	formation Disclosure Statement is submitted:			
[]	under 37 CFR 1.129(a), or			
	(First/Second submission after Final Rejection)			
[X]	under 37 CFR 1.97(b), or			
	(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)			
[]	under 37 CFR 1.97(c) together with either:			
	[] a Statement under 37 CFR 1.97(e), as checked below, or			
	[] a \$240.00 fee under 37 CFR 1.17(p), or			
	(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)			
[]	under 37 CFR 1.97(d) together with:			
	[] a Statement under 37 CFR 1.97(e), as checked below, and			
	[] a Petition under 37 CFR 1.97(d)(2), and			
	[] a \$130.00 petition fee set forth in 37 CFR 1.17(i). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)			
[]	Applicant requests that the attached IDS and cited reference(s) [] be placed in the application filewrapper. (Filed after payment of issue fee)			

[X] The listed references were cited in a Hungarian Search Report in a counter part Hungarian application.

Statement Under 37 CFR 1.97(e)

[X]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.			
[X]	Enclosed herewith is form PTO-1449, with copies of the references noted thereon; with a Certificate of Mailing, or			
[]	Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).			
Concis	e Explanation Requirement (non-English references):			
[X]	The "concise explanation" requirement for reference(s) HU P9802372 under 37 CFR 1.98(a)(3) is satisfied by:			
	[] the explanation provided on the attached sheet.			
	[] the explanation provided in the Specification.			
	[] submission of the enclosed International Search Report.			
	[X] the enclosed English language equivalent: US Patent Number 5,705,483.			
enclose	quested that the information disclosed herein be made of record in this application, and that the references listed on the 3d form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, 1302.12).			
Method	I of payment:			
[]	A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.			
[X]	No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.			
[X]	The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.			
	Respectfully submitted,			
	BIOMEASURE, INCORPORATED			
	By I lan Wyca Ruf			

12/11/2002 27 Maple Street

Milford, Massachusetts 01757

Alan F. Feeney, Attorney for Applicant Registration No.: 43,609

Telephone: (508) 478-0144 Facsimile: (508) 473-3531



PATENT APPICATION DOCKET NO.: 00537-191002

093/US/PCT2/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A 1' (C)	D 01.41 .1
Applicant(s):	Dean Sadat-Aalaee et al.

Application No.: 09/980,943

Group Art Unit: 1615

Filed:

February 22, 2002

Examiner:

Unknown

Title:

[X]

SOMATOSTATIN AGONISTS

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit:

5 //- 2002) Las Ly 4 et 1 / Alan F. Feeney

 $\frac{1^{\text{st}} \, \text{SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO}{\text{CHARGE DEPOSIT ACCOUNT}}$

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:			
This In	ormation Disclosure Statement under 37 CFR 1.129(a), or (First/Second submission after Final Rejec		
[X]	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)		
[]	under 37 CFR 1.97(c) together with either:		
	[] a Statement under 37	7 CFR 1.97(e), as checked below, or	
•	[] a \$240.00 fee under (After the 37 CFR 1.97(b) time period, but	37 CFR 1.17(p), or t before final action or notice of allowance, whichever o	occurs first)
[]	under 37 CFR 1.97(d) together with:		
	[] a Statement under 37	7 CFR 1.97(e), as checked below, and	
	[] a Petition under 37 (CFR 1.97(d)(2), and	
	·	ee set forth in 37 CFR 1.17(i). unce, whichever occurs first, but before payment of the is	ssue fee)
[]	Applicant requests that the att	tached IDS and cited reference(s) [] be placed in the application filewrapper.

The listed references were cited in a Hungarian Search Report in a counter part Hungarian application.

Statement Under 37 CFR 1.97(e)

[X]	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
[X]	Enclosed herewith is form PTO-1449, with copies of the references noted thereon; with a Certificate of Mailing, or				
[]	Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claim benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).				
Concis	e Explana	ation Requirement (non-English references):			
[X]	The "co	oncise explanation" requirement for reference(s) HU P9802372 under 37 CFR 1.98(a)(3) is satisfied by:			
	[]	the explanation provided on the attached sheet.			
	[]	the explanation provided in the Specification.			
	[]	submission of the enclosed International Search Report.			
	[X]	the enclosed English language equivalent: US Patent Number 5,705,483.			
enclose	juested the d form P 1302.12	at the information disclosed herein be made of record in this application, and that the references listed on the TO-1449 appear under the "References Cited" heading of any Patent which issues from this application,).			
Method	l of paym	ent:			
[]	A chec	s for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.			
[X]	No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.				
[X]	The As	sistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment osit Account 50-0590. Two copies of this Statement are enclosed.			
		Respectfully submitted,			
		BIOMEASURE, INCORPORATED			

Alan F. Feeney, Attorney for Applicant

Registration No.: 43,609 Telephone: (508) 478-0144 Facsimile: (508) 473-3531

Dated: /2/11/20

27 Maple Street

Milford, Massachusetts 01757